AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04457856 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TJ003234 injection
Description: Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks)
Study NCT04457856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TJ003234 injection
Description: Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks)
Study NCT01627132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100mg QD
Study NCT02119299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART device
Description: Sensor Monitored Alimentary Restriction Therapy (SMART) device
Study NCT02188550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus and letrozole
Description: This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally
Study NCT04260165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal Row Carpectomy
Description: Excision of the proximal carpal row - the scaphoid, lunate and triquetrum
Study NCT04260165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four-corner fusion
Description: Scaphoid excision and four-corner fusion with cannulated headless compression screws/dorsal plate
Study NCT02105324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Automated blood glucose control via a closed-loop bionic pancreas device.
Study NCT02105324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: As a comparator control, usual diabetes camp care with the participant's own insulin pump.
Study NCT00701831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: The dose is titrated according to patient needs
Study NCT03885973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Description: Fermented milk containing probiotic Lactobacillus plantarum for three weeks
Study NCT03885973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fermented milk containing placebo for three weeks
Study NCT00481663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Study NCT00481663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to sitagliptin
Study NCT00481663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Study NCT00481663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue
Description: Patients whose FPG >240 mg/dL from Week 16 or HbA1C >8.5% from Week 25 up to (not including) Week 52 could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1). Participants were eligible for rescue with pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed) if they met the following criteria: from Week 16 and during the second extension: FPG consistently >240 mg/dL (repeated and confirmed within 3 to 7 days); from Week 52 up to (not including) Week 70: HbA1C >8%; from Week 70 up to (not including) Visit 21/Week 106: HbA1C >7.5% (Extension 2). Participants placed on rescue therapy with pioglitazone (rosiglitazone where pioglitazone is not available) in the first or second extensions were not eligible for enrollment in the third extension. Rescue therapy was not available in the third extension.
Study NCT00481663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue
Description: Patients whose FPG >240 mg/dL from Week 16 or HbA1C >8.5% from Week 25 up to (not including) Week 52 could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1). Participants were eligible for rescue with pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed) if they met the following criteria: from Week 16 and during the second extension: FPG consistently >240 mg/dL (repeated and confirmed within 3 to 7 days); from Week 52 up to (not including) Week 70: HbA1C >8%; from Week 70 up to (not including) Visit 21/Week 106: HbA1C >7.5% (Extension 2). Participants placed on rescue therapy with pioglitazone (rosiglitazone where pioglitazone is not available) in the first or second extensions were not eligible for enrollment in the third extension. Rescue therapy was not available in the third extension.
Study NCT03895801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1
Description: intravenously administered
Study NCT03895801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IFX-1
Description: intravenously administered
Study NCT03895801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-IFX-1
Description: intravenously administered
Study NCT03895801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid (GC)
Description: orally administered
Study NCT03895801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid (GC)
Description: orally administered
Study NCT03895801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Glucocorticoid (Placebo-GC)
Description: orally administered
Study NCT00299039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen plus codeine
Description: capsules four times daily until pain free or for a maximum of seven days
Study NCT00299039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen plus ibuprofen
Description: capsules four times daily until pain free or for a maximum of seven days
Study NCT03885557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group I Experimental DOS
Description: After the application of hot pack treatment of 7-10 minutes, dynamic oscillatory stretch(DOS) technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
Study NCT03885557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group II SS group
Description: After the application of hot pack treatment of 7-10 minutes , Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
Study NCT03220503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial injury
Description: single induced injury will be done on the posterior endometrium on day 7 of the transfer cycle by using modified Cook catheter.
Study NCT01398241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5267683
Description: Multiple ascending doses
Study NCT01398241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Multiple ascending doses
Study NCT03170713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arveles
Description: 800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
Study NCT03170713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: arveles
Description: 800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
Study NCT03170713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrafen
Description: 800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
Study NCT03170713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrafen
Description: 800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
Study NCT03170713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebos
Description: 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
Study NCT01068236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle managment
Description: Exercise, yoga, food diaries, provider consultation
Study NCT03257267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous (IV) administration every 3 weeks (Q3W)
Study NCT03257267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigator Choice (IC) Chemotherapy
Description: IC chemotherapy options include:~1. Antifolate: Pemetrexed~2. Topoisomerase 1 inhibitor: Topotecan or Irinotecan~3. Nucleoside analogue: Gemcitabine~4. Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above.
Study NCT00635427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPRIV®
Description: Intravenous infusion, every other week (EOW)
Study NCT03583567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine and ranitidine
Description: Patient will receive intravenous chlorpheniramine and ranitidine prior to protamine.
Study NCT03583567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Patient will receive normal saline as placebo.
Study NCT03428529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Oral Product
Description: Neoadjuvant Capecitabine concomitant to external beam radiotherapy
Study NCT01955811 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Administration of platelet concentrate and taking blood samples
Description: Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
Study NCT03408899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC-1005 gel
Description: PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
Study NCT01631942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC172-2021
Description: Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation.
Study NCT02156258 — intervention group
Intervention type: DEVICE
Intervention: FFDM Mammography
Description: Standard mammography image collection
Study NCT02156258 — intervention group
Intervention type: DEVICE
Intervention: DBT Mammography
Description: Collection of breast images using DBT mammography
Study NCT01240746 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative
Description: 0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular
Study NCT01240746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative
Description: 0.25 mL (6 to 35 months) or 0.5 mL (3 to \<9 years), Intramuscular
Study NCT01240746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine, No Preservative
Description: 0.25 mL (6 to 35 months), or 0.5 mL(3 to \<9 years), Intramuscular
Study NCT03636256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDoce (direct injection)
Description: Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)
Study NCT03636256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDoce (intravesical instillation) - Visit 2 Instillation
Description: All subjects will receive an initial intravesical instillation within 2 hours of direct injection.
Study NCT03636256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Institutional Standard of Care
Description: Group 2 (MIBC) will receive institutional standard of care treatments after the Visit 2 intravesical instillation.
Study NCT03636256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
Description: Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
Study NCT03428529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil
Description: Neoadjuvant bolus 5-Fluorouracil concomitante to external beam radiotherapy
Study NCT06240923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary molars distalization
Description: Maxillary molars distalization by using a nickel titanium open coil spring as an posterior displacement device.
Study NCT02455193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02455193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Study NCT03485625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
Study NCT03485625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
Study NCT03485625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
Study NCT03173339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation using laryngoscope
Description: Endotracheal intubation was done using laryngoscope for general anesthesia.
Study NCT03173339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation using laryngoscope
Description: Endotracheal intubation was done using laryngoscope for general anesthesia.
Study NCT03173339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High remifentanil
Description: Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
Study NCT03173339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low remifentanil
Description: Remifentanil was administered as 0.1 mcg/kg/min.
Study NCT03173339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High sevoflurane
Description: Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
Study NCT03173339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low sevoflurane
Description: Sevoflurane was administered as 0.5 MAC.
Study NCT00599001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: Single subcutaneous escalating dose
Study NCT00599001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03299985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic myofascial release
Description: Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
Study NCT03299985 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham myofascial release
Description: Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
Study NCT03810443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperventilation test
Description: The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
Study NCT00879190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unasyn
Description: Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
Study NCT00879190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin/gentamicin
Description: Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
Study NCT02623192 — intervention group
Intervention type: OTHER
Intervention: Patients who have performed the ARDS pulmonary function test
Study NCT03837847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching Calls
Description: Participants in this group will receive 12 weekly health coaching calls
Study NCT03837847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in this group will receive 6 educational guides
Study NCT01323556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure
Study NCT01323556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
Study NCT01327794 — intervention group
Intervention type: GENETIC
Intervention: polymorphism analysis
Study NCT01327794 — intervention group
Intervention type: OTHER
Intervention: immunologic technique
Study NCT01327794 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT01327794 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Study NCT00726453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Zotarolimus-Eluting Coronary Stent
Description: Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
Study NCT01118299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMPLATZER Cardiac Plug
Description: AMPLATZER Cardiac Plug is a percutaneous transcatheter device
Study NCT01118299 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMPLATZER Cardiac Plug
Description: AMPLATZER Cardiac Plug is a percutaneous transcatheter device
Study NCT01067391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: 20 mg tablet, administered once per study protocol
Study NCT01067391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet administered once per study protocol
Study NCT00778050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 600mg